For patients with stage IV EGFR-mutated NSCLC with oligometastatic disease during first-line EGFR-TKI therapy, consolidative local ablative therapy of all residual lesions (including primary tumor, lymph nodes, and metastatic sites as appropriate) is performed. Here, EGFR is linked to non-small cell lung carcinoma.